arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

X4 Pharmaceuticals, Inc

XFOR
$3.12 ▼ -0.32 (-9.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
40 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

X4 Pharmaceuticals, Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $394.2M
Dividend Yield
Revenue Growth 346.3%
Op. Margin -186.1%
ROIC -7.1%
FCF / Share $-0.16
Trailing P/E
Price / Book 1.9x
FCF Yield
Debt / Equity 0.48
info Valuation on last close. End-of-day price, Sep 23, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.81M
↑ +346.3%
Net Income Profit after all expenses
$-20.24M
— 0.0%
Operating Margin Operating profit as % of sales
-186.1%
↓ -467.8% 0th
FCF / Share Free cash flow per share
$-0.16
↓ -6.0%
Long-Term Debt Long-term obligations
$75.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
18
Financial Health
43
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 40 quarters